Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised


Last Raised

$18.25M | 14 yrs ago

About InteKrin Therapeutics

InteKrin Therapeutics, Inc. is a privately-held clinical stage biopharmaceutical company based in Los Altos, California developing therapeutics for diabetes, obesity and metabolic disorders. The company was founded in 2005 by Denny Lanfear, a former Vice President and Officer of Amgen, and clinical endocrinologist Christos Mantzoros, M.D., DSc, FACP, FACE, Associate Professor of Medicine at Harvard Medical School. InteKrin's Scientific Advisory Board includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism as well as top scientists formerly with the Food and Drug Administration. Its lead product, INT131, is a novel SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) which is in Phase II clinical trials for diabetes. The company focuses on high value therapeutics in addressing unmet medical needs. To learn more about InteKrin, visit

InteKrin Therapeutics Headquarters Location

4300 El Camino Real Suite 201

Los Altos, California, 94022,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing InteKrin Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InteKrin Therapeutics is included in 2 Expert Collections, including Diabetes.



1,750 items


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

InteKrin Therapeutics Patents

InteKrin Therapeutics has filed 7 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Autoimmune diseases
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Diseases of liver, Diabetes, Hepatology, Syndromes, Rare diseases


Application Date


Grant Date



Related Topics

Diseases of liver, Diabetes, Hepatology, Syndromes, Rare diseases



  • When was InteKrin Therapeutics founded?

    InteKrin Therapeutics was founded in 2005.

  • Where is InteKrin Therapeutics's headquarters?

    InteKrin Therapeutics's headquarters is located at 4300 El Camino Real, Los Altos.

  • What is InteKrin Therapeutics's latest funding round?

    InteKrin Therapeutics's latest funding round is Series C.

  • How much did InteKrin Therapeutics raise?

    InteKrin Therapeutics raised a total of $41.25M.

  • Who are the investors of InteKrin Therapeutics?

    Investors of InteKrin Therapeutics include Sofinnova Ventures, Asset Management Ventures, Sears Capital Management, Vivo Capital, OrbiMed Advisors and 6 more.

  • Who are InteKrin Therapeutics's competitors?

    Competitors of InteKrin Therapeutics include Immunomic Therapeutics, Ambrx, Bicycle Therapeutics, Intarcia Therapeutics, Intercept Pharmaceuticals, InflaRx, KBI Biopharma, Nps Pharmaceuticals, Aldagen, GI Dynamics and 13 more.

You May Also Like

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Harkness Pharmaceuticals

Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.


Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute ( and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.